Kinins in the cardiovascular system

Immunopharmacology

Volumn 33, Issue 1-3, 1996, Pages 209-216

  Schölkens, Bernward A ^a  

^a SANOFI   (France)

Author keywords

ACE inhibitors; kallikrein kinin system; kinin receptor antagonists

Indexed keywords

ANGIOTENSIN; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; KININ; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; RAMIPRIL;

ANIMAL MODEL; CARDIOVASCULAR SYSTEM; CELL TYPE; CONFERENCE PAPER; ENDOTHELIUM CELL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR SMOOTH MUSCLE;

EID: 0030175970     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00061-6     Document Type: Conference Paper

References (49)

1. Abelous, J., Bardier, E. Les substances hypotensives de l'urine humaine normale. Compt. Rend. Soc. Biol. 66: 511-512, 1909.
2. Bao, G., Gohlke, P., Unger, T. Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models: J. Cardiovasc. Pharmacol 20 (suppl 9): S96-S99, 1992.
3. 2+ and nitric oxide in bradykinin-stimulated vascular endothelial cells. Circ. Res. 76: 922-924, 1995.
4. Bonner, G., Rütten, H., Chrosch, R., Krause, E. Dosistritation von Hoe 140 und Wirkungskontrolle durch Bradykimn. Z. Kardiol. 83 (suppl I): abstract 507, 1994.
5. Campbell, D.J., Kladis, A., Duncan, A.-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 21: 155-165, 1993.
6. Campbell, D.J., Duncan, A.-M., Kladis, A., Harrap S.B. Increased levels of bradykinin and its metabolites in tissues of young spontaneously hypertensive rats. J. of Hypertens. 13: 739-746, 1995.
7. 2-receptor antagonist. Br. J. Clin. Pharmacol. 38: 317-322, 1994.
8. Davidson, D.C., Peart, I., Turner, S., Sangster, M. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis. Lancet, 343: 1575, 1994.
9. Figueroa, C.D., Gonzalez, C.B., Grigoriev, S., Alla, S.A., Haasemann, M., Jarnagin, K., Müller-Esterl, W. Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J. Histochem. Cytochem. 43: 137-148, 1995.
10. 2 receptor in rat vascular tissue. Fourteenth International Symposium on Kinms, Kinin '95, Denver, Colorado, September 10-15, book of abstracts, 1995.
11. Frey, E.K. Zusammenhänge zwischen Herzarbeit und Nierentätigkeit. Arch. Klin. Chir. 142: 663, 1926.
12. Graf, K., Niehus, J., Baumgarten, C.R., Gräfe, M., Fleck, E., Kunkel, G. Role of endothelial cells in inflammatory processes. Int. Arch. Allergy Immunol. 99: 382-386, 1992.
13. Graf, K., Gräfe, M., Auch-Schwelk, W., Baumgarten, C.R., Scheffer, H., Hildebrandt, A., Fleck, E. Tissue kallikrein activity and kinin release in human endothelial cells. Eur. J. Clin. Chem. Clin. Biochem. 32: 495-500, 1994.
14. Groves, P., Kurz, S., Just, H., Drexler, H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation: in press.
15. Hashimoto, K., Hamamoto, H., Honda, Y., Hirose, M., Furukawa, S., Kimura, E. Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am. Heart J. 95: 619-626, 1978.
16. Jeserich, M., Hornig, B., Lohmann, A., Drexler, H., Just, H. Effects of acute ACE inhibition on conductance vessels, focus on bradykinin. Heart Failure '95. First Intern. Meeting of the Working Group on Heart Failure, European Society of Cardiology, Amsterdam, The Netherlands, April 1-4, book of abstracts, 1995a.
17. Jeserich, M., Hornig, B., Lohmann, A., Drexler, H. ACE inhibition increases flow-mediated dilation in the forearm of normal subjects. European Society of Cardiology, Amsterdam, book of abstracts, August 1995b.
18. Korth, P., Fink, E., Linz., W., Schölkens, B.A., Wohlfart, P., Wiemer, G. Angiotensin II receptor subtype-stimulated formation of endothelial cyclic GMP and prostacyclin is accompanied by an enhanced release of endogenous kinins. Pharm. Pharmacol. Lett, in press.
19. 9-bradykinin release following reperfusion of the ischaemic rat heart. Br. J. Pharmacol. in press.
20. Linz, W., Wiemer, G., Gohlke, P., Unger, T., Schölkens, B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47 (No. 1): 25-49, 1995.
21. Lochner, W., Parratt, J.R. A comparison of the effects of locally and systemically administered kinins on coronary blood flow and myocardial metabolism. Br. J. Pharmacol. 26: 17-26, 1966.
22. Majima, M., Katori, M. Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. TIPS, 16: 239-246, 1995.
23. Margolius, H.S. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension, 26: 221-229, 1995.
24. McDonald, K.M., Mock, J., D'Aloia, A., Parrish, T., Hauer, K., Francis, G., Stillman, A., Cohn, J.N. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 91: 2043-2048, 1995.
25. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ. Res. 76: 773-780, 1995.
26. Noda, K., Sasaguri, M., Ideishi, M., Ikeda, M., Arakawa, K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc. Res. 27: 334-340, 1993.
27. Nolly, H., Carretero, O.A., Scicli, G., Madeddu, P., Scicli, A.G. A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats. Hypertension. 16: 436-440, 1990.
28. Nolly, H., Carbini, L.A., Scicli, G., Carretero O.A., Scicli A.G. A local kallikrein-kinin system is present in rat hearts. Hypertension. 23: 919-923, 1994a.
29. Nolly, H., Carretero, O.A., Lama, M.C., Miatello, R., Scicli, A.G. Vascular kallikrein in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 23 (suppl 1): 1-185-1-188, 1994b.
30. Nolly, H., Damiani, M.T., Miatello, R. Vascular-derived kinins and local control of vascular tone. Brazilian J. Med. Biol. Res. 27: 1995-2011, 1994c.
31. Parratt, J.R. Protection of the heart by ischemic preconditioning: mechanisms and possibilities for pharmacological exploitation. TIPS 15: 19-25, 1994.
32. Pellacani, A., Brunner, H.R., Nussberger, J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin. Sci. 87: 567-574, 1994.
33. Pellacani, A., Cavallone, S., Veglio, F., Chiandussi, L., Nussberger, J. Plasma kinins increase after acute ACE inhibition with ramipril in patients with essential hypertension. Seventh European Meeting on Hypertension, European Society of Hypertension, Milan, Italy, June 9-12. book of abstracts, 1995.
34. Rubin, L.E., Levi, R. Protective role of bradykinin in cardiac anaphylaxis. Circ. Res. 76: 434-440, 1995.
35. Schmaier, A.H., Kuo, A., Lundberg, D., Murray, S., Cines, D. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J. Biol. Chem. 263: 16327-16333, 1988.
36. Seyedi, N., Xu, X.B., Nasjletti, A., Hintze, T.H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 26: 164-170, 1995.
37. Stauss, H.M., Adamiak, D., Zhu, Y.C., Redlich, T., Unger, T. ACE inhibition following myocardial infarction (MI) in kinin-deficient Brown-Norway Katholiek rats (BNK). Council of High Blood Pressure Research, 48th Annual Fall Conference and Scientific Sessions, Chicago, September 27-30. book of abstracts, 1994a.
38. Stauss, H.M., Zhu, Y.-C., Redlich, T., Adamiak, D., Mott, A., Kregel, K.C., Unger, T. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J. Cardiovasc. Risk, 1: 255-262, 1994b.
39. The acute infarction efficacy (AIRE) study investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342: 821-828, 1993.
40. Van Iwaarden, F., De Groot, P.G., Sixma, J.J., Bouma, B.N. High-molecular weight kininogen is present in cultured human endothelial cells: Localisation, isolation and characterisation. Blood, 71: 1268-1276, 1988.
41. Vavrek, R.J., Stewart, J.M. Development and modification of competitive antagonists of bradykinin. Proc. 9th Am. Peptide Symposium; Peptides, Structure and Function: 655-658, 1985.
42. Vegh, A., Papp, J.G., Parratt, J.R. Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anesthetized dogs. Br. J. Pharmacol. 110: 18-19, 1993.
43. 2 receptors. Br. J. Pharmacol. 113: 1167-1172, 1994.
44. Wall, T.M., Sheehy, R., Hartman, J.C. Role of bradykinin in myocardial preconditioning. J. Pharmacol. Exp. Ther. 270: 681-689, 1994.
45. Wang, J., Xiong, W., Yang, Z., Davis, T., Dewey, M.J., Chao, J., Chao, L. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension, 23: 236-243, 1994.
46. Wang, C., Chao, L., Chao, J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 95: 1710-1716, 1995.
47. Wiemer, G., Pierchala, B., Mesaros, S., Schölkens, B.A., Malinski, T. Direct measurement of nitric oxide release from cultured endothelial cells stimulated by bradykinin or ramiprilat. Endothelium: in press, 1995.
48. 1 antagonist in endothelial cells of different species. Fourteenth International Symposium on Kinins. Kinin '95, Denver, Colorado, September 10-15, book of abstracts, 1995.
49. 2 kinin receptors in cultured bovine aortic endothelial cells. J. Pharmacol. Exp. Ther. 262: 729-733, 1992.